MedTrace Logo

A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis

NCT02546323 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 543

Last updated 2019-12-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.

Conditions

Interventions

DRUG

Rosuvastatin

20mg tablets, orally once daily for the duration of the 104-week treatment period

DRUG

Placebo

Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.

Sponsors & Collaborators

Principal Investigators

  • Yongjun Wang, M.D. · Beijing Tian Tan Hospital, Capital Medical University

  • Yundai Chen, M.D. · Chinese PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-17
Primary Completion
2019-01-29
Completion
2019-01-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02546323 on ClinicalTrials.gov